The costs and complexities of managing and updating proprietary IT systems have driven some leading pharmaceutical companies to pursue an alternative model. By the end of this decade, many pharmaceutical companies’ R&D operations may no longer own or invest in their technology solutions.
The companies will turn to industry-wide services, similar to “utilities,” that provide transaction processing services and support the sharing of noncompetitive data across various corporate sponsors. This sharp change in direction is important for pharmaceutical companies if they expect to offset slowing growth rates to achieve bottom-line results.
This point of view provides insights into how automation can help streamline clinical data management when pharmaceutical companies team up for precompetitive collaborations.